Mackenzie Financial Corp Cytom X Therapeutics, Inc. Transaction History
Mackenzie Financial Corp
- $65 Billion
- Q1 2024
A detailed history of Mackenzie Financial Corp transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 18,138 shares of CTMX stock, worth $23,942. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,138
Previous 19,679
7.83%
Holding current value
$23,942
Previous $30,000
30.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CTMX
# of Institutions
89Shares Held
43.9MCall Options Held
105KPut Options Held
4.5K-
Bvf Inc San Francisco, CA6.6MShares$8.71 Million0.43% of portfolio
-
Tang Capital Management LLC San Diego, CA6.45MShares$8.51 Million1.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.86MShares$6.41 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.54MShares$4.68 Million0.17% of portfolio
-
Acadian Asset Management LLC Boston, MA2.69MShares$3.55 Million0.02% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $87.1M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...